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http://dx.doi.org/10.1016/j.gendis.20
2352-3042Abstract We devoted this short piece to highlight one recent article published in Science,
which revisited the anti-cancer efficacy of high-dose vitamin C. Using isogeneic KRAS- and
BRAF-mutated colorectal cell lines, the authors were able to demonstrate selective anti-
tumor effects among the KRAS- and BRAF-mutated cells in culture and in ex-planted animal
models treated with high-dose vitamin C. Their elegant and in-depth studies unequivocally tied
the tumoricidal effect to the heightened sensitivity of the mutant cells due to the increased
vitamin C uptake, leading to lethal accumulation of reactive oxygen species (ROS). This report
will certainly rekindle enthusiasm in revisiting the case of vitamin C, pushing for more defin-
itive cancer therapy trials.For decades, high-dose vitamin C, in either the oral or
intravenous form, has been examined for its efficacy in
anti-cancer therapy.1 So far, the studies of vitamin C have
been plagued with inconsistencies. When it was used alone
in in vitro and animal tests, high-dose vitamin C appeared
to show beneficial effects in suppressing the growth of
certain types of cancer cells. However, the combinations of
vitamin C with other chemotherapeutic agents largely
failed to show a complementary effect. Decades of clinical
trials dating back to the late 1970s met the same ill fate.
Vitamin C, either as a stand-alone agent or in combination
with other clinically approved chemotherapeutic agents,
has yet to prove itself a “cure” in anti-cancer therapy.
A substantial knowledge gap exists in understanding how
vitamin C, as a redox agent, can potentially target malig-
nant metabolic pathways to halt or kill cancer cells. To fill
this gap, an article published in a recent issue of Science
investigated the potential mechanism underlying the anti-
cancer effects of vitamin C using isogenic KRAS- and
BRAF-mutant colorectal cancer cell lines.2 The authors
were able to demonstrate selective anti-tumor effectsity of Chongqing Medical
15.12.001among the KRAS- and BRAF-mutated cells in culture and in
ex-planted animal models treated with high-dose vitamin
C. Their elegant and in-depth studies unequivocally tied
the tumoricidal effect to the heightened sensitivity of the
mutant cells due to the increased vitamin C uptake. This,
through intermediary biochemical steps, led to a lethal
accumulation of reactive oxygen species (ROS) within the
mutant cancer cells. In this outstanding work, the authors
laid out a clear and compelling rationale that vitamin C has
a promising role in cancer therapy, particularly in light of
the fact that KRAS- and BRAF-mutated cancer cells are
prone to resistance to certain classes of chemotherapeutic
agents. This report will certainly rekindle enthusiasm in
revisiting the case of vitamin C, pushing for more definitive
cancer therapy trials.
Ample clinical trials have demonstrated that what
worked in cell lines or mice may not be reproducible in
human subjects. In addition, vitamin C is not totally free
from side effects, especially when given in high doses. If
KRAS- and BRAF-mutated cancer cells are indeed sensitive
to ROS induced by high levels of intracellular vitamin C,
which leads to the inactivation of glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH), one would wonder if it may
be more effective to explore strategies to target GAPDH
2 View on newsdirectly without the need to administer high doses of
vitamin C. Due to the controversial history of the previous
vitamin C trials, especially those in conjunction with other
chemotherapeutic agents, the question remains whether
the “C” can stand for “cure” this time around.
Conflicts of interest
The authors declare no conflicts of interest.
Acknowledgments
Work in Dr. Zhang’s laboratory was supported in part by
research grants from the National Institutes of Health of the
USA (R01CA106348, R01CA172136 and R01CA203028)
References
1. PDQ Cancer Complementary and Alternative Medicine Editorial
Board.High-Dose Vitamin C (PDQ): Health Professional Version.
PDQ Cancer Information Summaries [Internet]. Bethesda (MD):
National Cancer Institute (US); 2002-.2015 Jun 29.2. Yun J, Mullarky E, Lu C, et al. Vitamin C selectively kills KRAS
and BRAF mutant colorectal cancer cells by targeting GAPDH.
Science. 2015;350:1391e1396.
Fei Li, Executive Associate Editor,*
The Editorial Office of Genes & Diseases, Chongqing, China
Lin Zhang
University of Pittsburgh Cancer Institute, Pittsburgh, PA,
USA
Shou-Ching Tang
Georgia Regents University Cancer Center, Augusta, GA,
USA
Tianjin Medical University Cancer Institute and Hospital,
Tianjin, China
*Corresponding author.
E-mail address: fei@genesndiseases.org (F. Li)
18 December 2015
